United States · Markets & Finance · Quartz

Novartis is licensing an mRNA autoimmune therapy from China's Abogen for up to $7.8 billion

Published by Quartz · United States 3 h ago

The Swiss drugmaker will pay $575 million upfront to license ABO2203, with up to $7.2 billion more tied to milestones

Read the full article on Quartz Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (qz.com)

Also worth reading

American starts letting customers mix cash and miles for tickets

LNG Shipments Through Hormuz Hit Highest Level Since Iran War Began

TechCrunch Disrupt 2026: Blackstone’s Jas Khaira on building the next generation of AI giants

iShares 20+ Year Treasury Bond BuyWrite Strategy ETF declares monthly distribution of $0.2885

Soft Jobs Report Boosts Market Bets Fed Will Skip October Rate Increase

Business Insider

The states where borrowers owe the most in federal student loans, ranked by average balance